Literature DB >> 2009059

Suppressive effects of visceral tumor on the generation of antitumor T cells for adoptive immunotherapy.

V K Sondak1, P D Wagner, S Shu, A E Chang.   

Abstract

Antitumor reactive cells can be generated from lymphoid organs of mice bearing subcutaneous (SC), but not liver or lung, tumors by in vitro sensitization with irradiated tumor and interleukin 2. To examine whether visceral tumors mediated tumor-induced suppression, in vitro sensitization cells were generated from mice bearing SC tumors with and without concomitant liver or lung tumors. Antitumor efficacy of these cells was assessed in adoptive immunotherapy experiments. The presence of visceral tumors suppressed the ability to generate therapeutic in vitro sensitization cells from mice with SC tumors. By establishing visceral tumors at different intervals in relationship to SC tumor inoculation, we found that visceral tumor appeared to suppress directly the development of a host immune response to SC tumor, rather than inhibit function of established immune cells. Our model affords a means to study mechanisms of tumor-induced immunosuppression.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2009059     DOI: 10.1001/archsurg.1991.01410280040005

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  8 in total

1.  Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery.

Authors:  W Asavaroengchai; Y Kotera; J J Mulé
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-15       Impact factor: 11.205

Review 2.  Making room for T cells.

Authors:  Gabriel N Maine; James J Mulé
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

3.  A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas.

Authors:  Crystal L Mackall; Eunice H Rhee; Elizabeth J Read; Hanh M Khuu; Susan F Leitman; Donna Bernstein; Merertu Tesso; Lauren M Long; David Grindler; Margret Merino; William Kopp; Maria Tsokos; Jay A Berzofsky; Lee J Helman
Journal:  Clin Cancer Res       Date:  2008-08-01       Impact factor: 12.531

4.  Tumor-induced immune suppression of in vivo effector T-cell priming is mediated by the B7-H1/PD-1 axis and transforming growth factor beta.

Authors:  Shuang Wei; Andrew B Shreiner; Nobuhiro Takeshita; Lieping Chen; Weiping Zou; Alfred E Chang
Journal:  Cancer Res       Date:  2008-07-01       Impact factor: 12.701

5.  Induction of immunity to neuroblastoma early after syngeneic hematopoietic stem cell transplantation using a novel mouse tumor vaccine.

Authors:  Weiqing Jing; Rimas J Orentas; Bryon D Johnson
Journal:  Biol Blood Marrow Transplant       Date:  2007-03       Impact factor: 5.742

6.  Tumour cell contamination of autologous stem cells grafts in high-risk neuroblastoma: the good news?

Authors:  R Handgretinger; W Leung; K Ihm; P Lang; T Klingebiel; D Niethammer
Journal:  Br J Cancer       Date:  2003-06-16       Impact factor: 7.640

Review 7.  Activation of T lymphocytes for the adoptive immunotherapy of cancer.

Authors:  J J Sussman; S Shu; V K Sondak; A E Chang
Journal:  Ann Surg Oncol       Date:  1994-07       Impact factor: 5.344

8.  Ability of low-dose cyclophosphamide to overcome metastasis-induced immunosuppression.

Authors:  T M Tuttle; M D Fleming; P S Hogg; T H Inge; H D Bear
Journal:  Ann Surg Oncol       Date:  1994-01       Impact factor: 5.344

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.